01—Abstract
Summary
Summary of the 8-K filed June 22, 2026. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation (INCY) disclosed under Item 8.01 (Other Events) that it has reached an agreement with the Centers for Medicare & Medicaid Services (CMS) to resolve its litigation over the application of Medicaid rebate rules to Opzelura (ruxolitinib) cream.
Under the agreement, CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi (ruxolitinib), and the company has withdrawn its lawsuit challenging the regulations. The settlement was reached based on the unique facts of Opzelura and Jakafi. As a result, the company expects to record a one-time, non-cash benefit of approximately $246 milliona in the second quarter ending June 30, 2026.
This benefit reflects the reversal of previously established accrual balances through March 31, 2026, related to liabilities tied to the potential application of the line extension regulations to Opzelura. The company will no longer accrue for that potential application and expects an improvement to Opzelura's gross-to-net on a go-forward basis. The company plans to update its financial guidance to reflect the settlement's impact during its next scheduled earnings release.
02—Key points
Key Highlights
- Incyte reached an agreement with CMS resolving its litigation over Medicaid rebate rules applied to Opzelura (ruxolitinib) cream, and has withdrawn its lawsuit challenging the regulations.
- CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi (ruxolitinib); the settlement is based on the unique facts of Opzelura and Jakafi.
- Expected one-time, non-cash benefit of approximately $246 million in the second quarter ending June 30, 2026.
- The benefit results from reversing previously established accrual balances through March 31, 2026, related to potential line extension liabilities for Opzelura.
- No further accruals will be recorded for potential application of the line extension regulations to Opzelura.
- Company expects an improvement to Opzelura's gross-to-net on a go-forward basis.
- Financial guidance will be updated to reflect the settlement's impact at the next scheduled earnings release.
03—Questions
Frequently Asked Questions
What is the financial impact of the CMS settlement on Incyte?
Incyte expects to record a one-time, non-cash benefit of approximately $246 million in the second quarter ending June 30, 2026, from reversing previously established accrual balances through March 31, 2026.
What does the settlement mean for Opzelura's future Medicaid liabilities?
CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi. Incyte will no longer accrue for the potential application of these regulations to Opzelura and expects an improvement to Opzelura's gross-to-net on a go-forward basis.
Did Incyte withdraw its lawsuit against CMS?
Yes. Under the agreement, the company has withdrawn its lawsuit challenging the regulations related to the application of Medicaid rebate rules to Opzelura.
When will Incyte update its financial guidance?
The company plans to update its financial guidance to reflect the impact of the settlement during its next scheduled earnings release.
Why was the settlement reached on these terms?
According to the filing, the settlement was reached based on the unique facts of Opzelura and Jakafi.
04—Continue